Patent intelligence · US
US 11780930
CD38 modulating antibody
CD38 modulating antibody
Patent details — US 11780930
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 10, 2023
- Expiration
- Oct 5, 2043
- Applicant
- BLACK BELT THERAPEUTICS LIMITED
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 11780930 (CD38 modulating antibody) is held by BLACK BELT THERAPEUTICS LIMITED. Status: granted. Granted Oct 10, 2023. Expires Oct 5, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BLACK BELT THERAPEUTICS LIMITED
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from BLACK BELT THERAPEUTICS LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted
Frequently asked questions
What is US patent 11780930?
US 11780930 (CD38 modulating antibody) is held by BLACK BELT THERAPEUTICS LIMITED. Status: granted. Granted Oct 10, 2023. Expires Oct 5, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11780930?
BLACK BELT THERAPEUTICS LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 11780930 expire?
Our index shows an expiration date of Oct 5, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.